Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy

Journal of Clinical Microbiology

Volumn 48, Issue 7, 2010, Pages 2586-2588

  Sarmati, L ^a   Parisi, S G ^b   Andreoni, C ^c   Nicastri, E ^d   Buonomini, A R ^a   Boldrin, C ^b   Dori, L ^a   Montano, M ^a   Tommasi, C ^d   Andreis, S ^b   Vullo, V ^c   Palu G ^b   Andreoni, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CD4 LYMPHOCYTE COUNT; GENE SWITCHING; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; VIREMIA; VIRUS DETECTION; VIRUS STRAIN; ADULT; CLASSIFICATION; DISEASE COURSE; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MIDDLE AGED; PATHOGENICITY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VIRAL TROPISM; VIROLOGY;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; VIRAL TROPISM;

EID: 77954444321     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02125-09     Document Type: Article

References (19)

1. Blaak, H., A. B. van't Wout, M. Brouwer, B. Hooibrink, E. Hovenkamp, and H. Schuitemaker. 2000. In vivo HIV-1 infection of CD45RA(R) CD4(R) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(R) T cell decline. Proc. Natl. Acad. Sci. U. S. A. 97:1269-1274.
2. Brumme, Z. L., W. W. Dong, B. Yip, B. Wynhoven, N. G. Hoffman, R. Swanstrom, et al. 2004. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS 18:F1-F9.
3. Reference deleted.
4. Ercoli, L., L. Sarmati, E. Nicastri, G. Giannini, C. Galluzzo, S. Vella, and M. Andreoni. 1997. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 11:1211-1217.
5. Garrido, C., V. Roulet, N. Chueca, E. Poveda, A. Aguilera, K. Skrabal, et al. 2008. Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. J. Clin. Microbiol. 46:887-891.
6. Jekle, A., O. T. Keppler, E. De Clercq, D. Schols, M. Weinstein, and M. A. Goldsmith. 2003. In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J. Virol. 77:5846-5854.
7. Jensen, M., F. Li, A. van't Wout, et al. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J. Virol. 77:13376-13388.
8. Jensen, M., M. Coetzer, A. van't Wout, D. C. Nickle, D. Shriner, H. X. He, et al. 2006. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J. Virol. 80:4698-4704.
9. Koot, M., I. P. Keet, A. H. Vos, R. E. de Goede, M. T. Roos, R. A. Coutinho, et al. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann. Intern. Med. 118: 681-688.
10. Kreisberg, J. F., D. Kwa, B. Schramm, V. Trautner, R. Connor, H. Schuitemaker, et al. 2001. Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status. J. Virol. 75:8842-8847.
11. Maggiolo, F., D. Ripamonti, G. Gregis, G. Quinzan Callegaro, and F. Suter. 2004. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4s: a controlled, prospective trial. AIDS 18:439-446.
12. Moncunill, G., M. Armand-Ugon, E. Pauls, B. Clotet, and J. A. Este. 2008. In vitro HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants. AIDS 22:23-31.
13. 6 cells/l. AIDS 19:287-294.
14. Raymond, S., P. Delobel, M. Mavigner, M. Cazabat, C. Souyris, K. Sandres-Sauné, L. Cuzin, B. Marchou, P. Massip, and J. Izopet. 2008. Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS 22:F11-F16.
15. Sarmati, L., C. Andreoni, E. Nicastri, C. Tommasi, A. Buonomini, G. D'Ettorre, et al. 2009. Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment. J. Med. Virol. 81:481-487.
16. Schuitemaker, H., N. A. Kootstra, R. E. de Goede, F. de Wolf, F. Miedema, and M. Tersmette. 1991. Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J. Virol. 65:356-363.
17. Tarwater, P., M. Parish, and J. Gallant. 2003. Prolonged treatment interruption after immunologic response to highly active therapy. Clin. Infect. Dis. 37:1541-1548.
18. 3. J. Infect. Dis. 192:1787-1793.
19. Westby, M., M. Lewis, J. Whitcomb, M. Youle, L. Anton Pozniak, Ian T. James, et al. 2006. Emergence of CXCR4-using human immunodeficiency virus type 1(HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J. Virol. 80:4909-4920.